Law360, New York (September 23, 2009) -- AstraZeneca Pharmaceuticals LP has lost an appeal of a $12.9 million decision in litigation over average wholesale drug prices and earned a fresh rebuke from the appeals court for its “unfair and deceptive” pricing policies.
Responding to a “panoply of challenges” by AstraZeneca, the U.S. Court of Appeals for the First Circuit found that the trial court ruled without committing material legal error, abusing its...
